Arlen Stone, MD
Family Medicine · Newark, DENPI 1396703765
Payments from drug & device makers
Across 638 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- AstraZeneca$931
- Pfizer$911
- Lilly USA, LLC$783
- Astellas Pharma US Inc$655
- plus $5K from 37 others
What the payments were for
- Food & beverage$10,24198%
- Education$1802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,421 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 28 | $42,695 |
| MounjaroTirzepatide | 29 | $27,216 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $25,821 |
| JardianceEmpagliflozin | 21 | $22,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $18,553 |
| EliquisApixaban | 15 | $10,557 |
| Atorvastatin Calcium | 117 | $1,917 |
| Ezetimibe | 46 | $1,829 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 20 | $1,821 |
| Pioglitazone Hcl | 36 | $1,650 |
| Rosuvastatin Calcium | 53 | $1,575 |
| Levothyroxine Sodium | 88 | $1,460 |
| Omeprazole | 63 | $1,289 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,221 |
| Levocetirizine Dihydrochloride | 25 | $824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimGlyxambi, Jardiance | $231 | $48,81936 claims |
| MerckJanuvia | $578 | $42,69528 claims |
| Lilly USA, LLCMounjaro | $783 | $27,21629 claims |
| GSKTrelegy Ellipta | $1,176 | $18,55314 claims |
| PfizerEliquis | $911 | $10,55715 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $23613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Ian MyersNewark$17K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Imelyn LaheyNewark$8K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
- William FunkNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.